Review article · 2025 · Open access

The Potential of Artificial Intelligence in Pharmaceutical Innovation: From Drug Discovery to Clinical Trials

Vera Malheiro, Beatriz Santos, Ana Figueiras, Filipa Mascarenhas‐Melo

Pharmaceuticals, 18(6), 788 · Published 25 May 2025 · DOI 10.3390/ph18060788

Free PDFView at the publisherCite this paper

In brief

“The Potential of Artificial Intelligence in Pharmaceutical Innovation: From Drug Discovery to Clinical Trials” is a 2025 review article by Vera Malheiro and 3 co-authors, published in Pharmaceuticals. OpenAlex counts 88 citations as of 15 November 2026. It is open access under a CC BY licence: the full text is free to read at Pharmaceuticals.

Citations
88
Most cited in
2026 (63)
Field-weighted impact
4.29
References
109
Authors
4

Abstract

Artificial intelligence (AI) is a subfield of computer science focused on developing systems that can execute tasks traditionally associated with human intelligence. AI systems work through algorithms based on rules or instructions that enable the machine to make decisions. With the advancement of science, more sophisticated AI techniques, such as machine learning and deep learning, have been developed, allowing machines to learn from large amounts of data and improve their performance over time. The pharmaceutical industry has greatly benefited from the development of this technology. AI has revolutionized drug discovery and development by enabling rapid and effective analysis of vast volumes of biological and chemical data during the identification of new therapeutic compounds. The algorithms developed can predict the efficacy, toxicity, and possible adverse effects of new drugs, optimize the steps involved in clinical trials, reduce associated time and costs, and facilitate the implementation of innovative drugs in the market, making it easier to develop precise therapies tailored to the individual genetic profile of patients. Despite significant advancements, there are still gaps in the application of AI, particularly due to the lack of comprehensive regulation. The constant evolution of this technology requires ongoing and in-depth legislative oversight to ensure its use remains safe, ethical, and free from bias. This review explores the role of AI in drug development, assessing its potential to enhance formulation, accelerate discovery, and repurpose existing medications. It highlights AI's impact across all stages, from initial research to clinical trials, emphasizing its ability to optimize processes, drive innovation, and improve therapeutic outcomes.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Malheiro, V., Santos, B., Figueiras, A., & Mascarenhas‐Melo, F. (2025). The Potential of Artificial Intelligence in Pharmaceutical Innovation: From Drug Discovery to Clinical Trials. Pharmaceuticals, 18(6), 788. https://doi.org/10.3390/ph18060788

MLA 9

Malheiro, Vera, et al. “The Potential of Artificial Intelligence in Pharmaceutical Innovation: From Drug Discovery to Clinical Trials.” Pharmaceuticals, vol. 18, no. 6, 2025, p. 788. https://doi.org/10.3390/ph18060788.

Chicago

Malheiro, Vera, Beatriz Santos, Ana Figueiras, and Filipa Mascarenhas‐Melo. 2025. “The Potential of Artificial Intelligence in Pharmaceutical Innovation: From Drug Discovery to Clinical Trials.” Pharmaceuticals 18 (6): 788. https://doi.org/10.3390/ph18060788.

Harvard

Malheiro, V. et al. (2025) ‘The Potential of Artificial Intelligence in Pharmaceutical Innovation: From Drug Discovery to Clinical Trials’, Pharmaceuticals, 18(6), p. 788. doi:10.3390/ph18060788.

IEEE

V. Malheiro, B. Santos, A. Figueiras, and F. Mascarenhas‐Melo, “The Potential of Artificial Intelligence in Pharmaceutical Innovation: From Drug Discovery to Clinical Trials,” Pharmaceuticals, vol. 18, no. 6, p. 788, 2025, doi: 10.3390/ph18060788.

BibTeX

@article{malheiro2025potential,
  title     = {{The Potential of Artificial Intelligence in Pharmaceutical Innovation: From Drug Discovery to Clinical Trials}},
  author    = {Malheiro, Vera and Santos, Beatriz and Figueiras, Ana and Mascarenhas‐Melo, Filipa},
  journal   = {Pharmaceuticals},
  year      = {2025},
  volume    = {18},
  number    = {6},
  pages     = {788},
  doi       = {10.3390/ph18060788},
  url       = {https://doi.org/10.3390/ph18060788}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202411
20252424
20266363

Its field-weighted citation impact is 4.29: it has been cited 4.29 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods

  • artificial intelligence
  • pharmaceutical innovation
  • drug discovery
  • clinical trials
  • machine learning
  • deep learning
  • drug repurposing
  • drug formulation

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

Malheiro, V., Santos, B., Figueiras, A., & Mascarenhas‐Melo, F. (2025). The Potential of Artificial Intelligence in Pharmaceutical Innovation: From Drug Discovery to Clinical Trials. Pharmaceuticals, 18(6), 788. https://doi.org/10.3390/ph18060788

How many times has this paper been cited?

88 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at Pharmaceuticals.

Who wrote this paper?

Vera Malheiro, Beatriz Santos, Ana Figueiras, Filipa Mascarenhas‐Melo.

What is the DOI of this paper?

10.3390/ph18060788. The permanent link is https://doi.org/10.3390/ph18060788.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.